SAN DIEGO--(EON: Enhanced Online News)--DermTech, a privately held biotechnology company developing and commercializing qPCR assays for skin samples collected non-invasively using adhesive patch methods, announced today that its abstract entitled “Reproducibility and accuracy of cross platform rtqPCR testing for the detection of mRNA from surface squamous cells overlying pigmented skin lesions” has been accepted and will be presented by Dr. Howard Robin at the 2013 Annual Association for Molecular Pathology Meeting to be held November 14-16, 2013 at the Phoenix Convention Center.
“The research to be presented further demonstrates the validity of the DermTech pigmented lesion assay using a high throughput qPCR platform from Life Technologies.”
Clinical evaluation of pigmented skin lesions to determine malignancy is subjective and imperfect. Pathologic evaluation of the same lesions is also subjective, and well-trained pathologists often disagree about the diagnosis. DermTech has previously reported on the identification of gene expression signatures associated with melanoma using mRNA extracted from surface skin cells collected using a non-invasive adhesive patch. These studies have demonstrated >95% sensitivity and >70% sensitivity in several clinical studies, including one study published in the British Journal of Dermatology.
“There is a need for an objective method to evaluate pigmented skin lesions,” stated Dr. Robin, an anatomic and clinical pathologist who serves as Medical Director at DermTech. “The research to be presented further demonstrates the validity of the DermTech pigmented lesion assay using a high throughput qPCR platform from Life Technologies.”
Recently, DermTech completed a Series B financing and initiated commercial-validation testing of its proprietary pigmented lesion assay. The Company’s proprietary assays can analyze multiple gene targets to assess their level of gene expression. The Company will initially offer a novel assay that identifies expression consistent with melanoma.
Headquartered in La Jolla, California, DermTech is focused on the development of proprietary qPCR assays for dermatology. DermTech’s assays can be used with skin samples collected non-invasively via adhesive patch methods. The RNA from these samples is isolated, amplified, and analyzed using molecular biology tools to determine genetic expression profiles for a range of dermatologic conditions. DermTech is actively pursuing the development of an assay that can assess gene expression consistent with melanoma. For additional information visit: www.dermtech.com.